These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 25515952)

  • 1. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
    Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
    Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy.
    Wenter V; Herlemann A; Fendler WP; Ilhan H; Tirichter N; Bartenstein P; Stief CG; la Fougère C; Albert NL; Rominger A; Gratzke C
    Oncotarget; 2017 Jul; 8(27):44131-44140. PubMed ID: 28484088
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ahmadzadehfar H; Azgomi K; Hauser S; Wei X; Yordanova A; Gaertner FC; Kürpig S; Strunk H; Essler M
    J Nucl Med; 2017 Mar; 58(3):438-444. PubMed ID: 27660148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
    Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
    Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
    Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
    Parker CC; Pascoe S; Chodacki A; O'Sullivan JM; Germá JR; O'Bryan-Tear CG; Haider T; Hoskin P
    Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
    Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; Yachnin J; Garkavij M; Strang P; Harmenberg J; Bolstad B; Bruland OS
    Lancet Oncol; 2007 Jul; 8(7):587-94. PubMed ID: 17544845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
    Jadvar H; Challa S; Quinn DI; Conti PS
    Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital.
    Nakashima K; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Matsuo S; Mizokami A
    Anticancer Res; 2019 May; 39(5):2607-2614. PubMed ID: 31092459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
    Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
    PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
    Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
    Wang ZL; Wang XF
    Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pre-treatment variables on the completion of
    Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
    Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
    Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
    Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer.
    Wong WW; Anderson EM; Mohammadi H; Daniels TB; Schild SE; Keole SR; Choo CR; Tzou KS; Bryce AH; Ho TH; Quevedo FJ; Vora SA
    Clin Genitourin Cancer; 2017 Dec; 15(6):e969-e975. PubMed ID: 28545997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radium-223 dichloride therapy in breast cancer with osseous metastases.
    Takalkar A; Paryani B; Adams S; Subbiah V
    BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26581701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
    Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
    Wymenga LF; Boomsma JH; Groenier K; Piers DA; Mensink HJ
    BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.